Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker HUMA
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | Keith Anthony Jones Director | HUMA Humacyte, Inc. | Buy | 10,000 | $0.56 | $5,600 Buy | Form 4 ↗ |
| Aug 20, 2026 | Keith Anthony Jones Director | HUMA Humacyte, Inc. | Buy | 10,000 | $0.69 | $6,900 Buy | Form 4 ↗ |
| Aug 17, 2026 | Keith Anthony Jones Director | HUMA Humacyte, Inc. | Buy | 30,000 | $0.59 | $17.7K Buy | Form 4 ↗ |
| May 19, 2026 | Kathleen Sebelius Director | HUMA Humacyte, Inc. | Buy | 56,818 | $0.88 | $50.0K Buy | Form 4 ↗ |
| May 18, 2026 | Shamik J. Parikh Chief Medical Officer | HUMA Humacyte, Inc. | Sale | 45,887 | $0.90 | $41.3K Sale | Form 4 ↗ |
| May 18, 2026 | Dale A. Sander CFO and Chief Corp. Dev. Off | HUMA Humacyte, Inc. | Sale | 45,887 | $0.90 | $41.3K Sale | Form 4 ↗ |
| May 18, 2026 | Michael T. Constantino Director | HUMA Humacyte, Inc. | Buy | 11,000 | $0.89 | $9,790 Buy | Form 4 ↗ |
| Aug 20, 2025 | Brady W. Dougan Director | HUMA Humacyte, Inc. | Sale | 591,685 | $1.58 | $934.9K Sale | Form 4 ↗ |
| Aug 20, 2025 | Laura E. Niklason President, CEO and Director, Director | HUMA Humacyte, Inc. | Sale | 591,685 | $1.58 | $934.9K Sale | Form 4 ↗ |
| Aug 19, 2025 | Brady W. Dougan Director | HUMA Humacyte, Inc. | Sale | 1.10M | $1.63 | $1.8M Sale | Form 4 ↗ |
| Aug 19, 2025 | Laura E. Niklason President, CEO and Director, Director | HUMA Humacyte, Inc. | Sale | 1.10M | $1.63 | $1.8M Sale | Form 4 ↗ |
| Aug 18, 2025 | Brady W. Dougan Director | HUMA Humacyte, Inc. | Sale | 549,360 | $1.83 | $1.0M Sale | Form 4 ↗ |
| Aug 18, 2025 | Laura E. Niklason President, CEO and Director, Director | HUMA Humacyte, Inc. | Sale | 549,360 | $1.83 | $1.0M Sale | Form 4 ↗ |
| Apr 14, 2025 | William John Scheessele Chief Commercial Officer | HUMA Humacyte, Inc. | Buy | 6,493 | $1.54 | $9,999 Buy | Form 4 ↗ |
| Apr 10, 2025 | Dale A. Sander CFO and Chief Corp. Deve. Off. | HUMA Humacyte, Inc. | Buy | 20,000 | $1.53 | $30.6K Buy | Form 4 ↗ |
| Apr 10, 2025 | Shamik J. Parikh Chief Medical Officer | HUMA Humacyte, Inc. | Buy | 7,500 | $1.55 | $11.6K Buy | Form 4 ↗ |
| Apr 8, 2025 | Kathleen Sebelius Director | HUMA Humacyte, Inc. | Buy | 50,000 | $1.32 | $66.0K Buy | Form 4 ↗ |
| Apr 8, 2025 | Charles Bruce Green Director | HUMA Humacyte, Inc. | Buy | 6,000 | $1.29 | $7,740 Buy | Form 4 ↗ |
| Apr 7, 2025 | Michael T. Constantino Director | HUMA Humacyte, Inc. | Buy | 16,000 | $1.26 | $20.2K Buy | Form 4 ↗ |
| Dec 4, 2024 | Michael T. Constantino Director | HUMA Humacyte, Inc. | Buy | 4,600 | $4.39 | $20.2K Buy | Form 4 ↗ |
| Nov 20, 2024 | Laura E. Niklason President, CEO and Director, Director | HUMA Humacyte, Inc. | Sale | 261,369 | $4.40 | $1.2M Sale | Form 4 ↗ |
| Nov 20, 2024 | Brady W. Dougan Director | HUMA Humacyte, Inc. | Sale | 261,369 | $4.40 | $1.2M Sale | Form 4 ↗ |
| Nov 19, 2024 | Laura E. Niklason President, CEO and Director, Director | HUMA Humacyte, Inc. | Buy | 1,797 | $4.44 | $7,979 Buy | Form 4 ↗ |
| Nov 19, 2024 | Brady W. Dougan Director | HUMA Humacyte, Inc. | Buy | 1,797 | $4.44 | $7,979 Buy | Form 4 ↗ |
| Nov 19, 2024 | Laura E. Niklason President, CEO and Director, Director | HUMA Humacyte, Inc. | Sale | 427,459 | $4.34 | $1.9M Sale | Form 4 ↗ |
| Nov 19, 2024 | Brady W. Dougan Director | HUMA Humacyte, Inc. | Sale | 427,459 | $4.34 | $1.9M Sale | Form 4 ↗ |
| Nov 18, 2024 | Laura E. Niklason President, CEO and Director, Director | HUMA Humacyte, Inc. | Sale | 811,172 | $4.44 | $3.6M Sale | Form 4 ↗ |
| Nov 18, 2024 | Brady W. Dougan Director | HUMA Humacyte, Inc. | Sale | 811,172 | $4.44 | $3.6M Sale | Form 4 ↗ |
28 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:16 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances